Dutch guideline on necrotizing soft tissue infections
In 2018 the first Dutch guideline on necrotizing soft tissue infections (NSTIs) was drafted. Its aim is to standardize the care of this disease in order to reduce variation, and thereby improve the quality of care. This guideline is a benchmark for all healthcare providers who deal with this devastating disease; it focuses on diagnostics, treatment options and organization of care. Given the low incidence, the complexity and the fulminant course of NSTIs, it is important to ensure continuous specialized care. Therefore it is recommended to make regional agreements about referral to specialized centres. Surgical exploration remains the gold standard for diagnosis. The empirical antibiotic regimen depends on if the onset of disease is community or nosocomial, and if its aetiology is a monomicrobial (type I) or a polymicrobial (type II). The guideline recommends that intravenous immunoglobulin (IVIg) therapy be started if gram staining reveals streptococci. IVIg must be discontinued if group-A streptococcus is excluded as a causative agent.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:164 |
|---|---|
| Enthalten in: |
Nederlands tijdschrift voor geneeskunde - 164(2020) vom: 06. Apr. |
| Sprache: |
Niederländisch |
|---|
| Weiterer Titel: |
Richtlijn ‘Necrotiserende wekedeleninfecties’ |
|---|
| Beteiligte Personen: |
Niessen, F A [VerfasserIn] |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 03.05.2021 Date Revised 03.05.2021 published: Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM309751721 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309751721 | ||
| 003 | DE-627 | ||
| 005 | 20231225134614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||dut c | ||
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM309751721 | ||
| 035 | |a (NLM)32392003 | ||
| 035 | |a (PII)D4737 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a dut | ||
| 100 | 1 | |a Niessen, F A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dutch guideline on necrotizing soft tissue infections |
| 246 | 3 | 3 | |a Richtlijn ‘Necrotiserende wekedeleninfecties’ |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.05.2021 | ||
| 500 | |a Date Revised 03.05.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In 2018 the first Dutch guideline on necrotizing soft tissue infections (NSTIs) was drafted. Its aim is to standardize the care of this disease in order to reduce variation, and thereby improve the quality of care. This guideline is a benchmark for all healthcare providers who deal with this devastating disease; it focuses on diagnostics, treatment options and organization of care. Given the low incidence, the complexity and the fulminant course of NSTIs, it is important to ensure continuous specialized care. Therefore it is recommended to make regional agreements about referral to specialized centres. Surgical exploration remains the gold standard for diagnosis. The empirical antibiotic regimen depends on if the onset of disease is community or nosocomial, and if its aetiology is a monomicrobial (type I) or a polymicrobial (type II). The guideline recommends that intravenous immunoglobulin (IVIg) therapy be started if gram staining reveals streptococci. IVIg must be discontinued if group-A streptococcus is excluded as a causative agent | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 700 | 1 | |a de Jong, V M |e verfasserin |4 aut | |
| 700 | 1 | |a Janssen, S |e verfasserin |4 aut | |
| 700 | 1 | |a Boel, C H E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nederlands tijdschrift voor geneeskunde |d 1946 |g 164(2020) vom: 06. Apr. |w (DE-627)NLM000034231 |x 1876-8784 |7 nnns |
| 773 | 1 | 8 | |g volume:164 |g year:2020 |g day:06 |g month:04 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 164 |j 2020 |b 06 |c 04 | ||